ロード中...
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
BACKGROUND: Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemo-therapy. Effective therapies with acceptable side-effect profiles are needed for this patient population. METHODS: In this multi...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4161365/ https://ncbi.nlm.nih.gov/pubmed/24450857 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1315226 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|